Children who inherit genetic mutations from parents with early-onset Alzheimer’s typically show signs of dementia at the same ...

The Washington University trial comes as part of a larger platform study which hopes to understand if Alzheimer's disease can ...

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker came out with a mostly better-than-expected 2025 forecast.

Eli Lilly is set to report fourth-quarter earnings early Thursday, with analysts expecting rising sales and profit in the first full quarter with the company's weight-loss drugs no longer in shortage.

Eli Lilly exceeded analyst forecasts for both sales and earnings in Q4 2024. As has been true for a while, sales of GLP-1 drugs Mounjaro and Zepbound drove both sales and earnings growth.

Eli Lilly (NYSE:LLY) is setting the stage for a strong 2025, with its fourth-quarter results and forward guidance reflecting solid momentum. The company's adjusted earnings per share are expected ...

Eli Lilly (LLY) stock is higher Thursday after the pharmaceutical company beat profit expectations and matched revenue forecasts for its fourth quarter and issued a better-than-expected outlook ...

Eli Lilly (NYSE: LLY) stock inched 2.5% higher through 9:50 a.m. ET Thursday after beating on the top and bottom lines in this morning's Q4 earnings report. Heading into the report, analysts ...